Clinical Trial Update: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant breast cancer trial at Fudan University Shanghai Cancer Center evaluating a precision-platform therapy; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-negative Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Breast Neoplasm, Breast Cancer | Phase 2 | Status: RECRUITING